Eli Lilly says Kisunla demonstrated ‘meaningful results’ for people showing early symptoms of the disease
Federal health authorities on Tuesday gave approval to an experimental new drug that has shown to delay the onset of Alzheimer’s disease in trials.
Donanemab, manufactured by Eli Lilly, is the second medication that has won the blessing of the Food and Drug Administration (FDA) to treat patients showing early symptoms of the disease, most prominently cognitive impairment.
More Stories
Everyone hates cane toads – even the other cane toads | First Dog on the Moon
Scientists find ‘mutant’ gene behind foul-smelling species of wild ginger
The Guardian view on drought warnings: risks to the food supply need confronting | Editorial